MCM3AP

Across TCGA pan-cancer cohorts, MCM3AP Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated MCM3AP data layer compared with 22 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher MCM3AP Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MCM3AP expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

THYM, MESO, and LUSC are the cancer types where MCM3AP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
MESO	OS	Median	III,IV	0.052	0.567	<.001	36	view →
LUSC	DFS	Median	All	0.156	0.712	.004	14	view →
COAD	DFS	Median	All	0.453	0.795	.021	13	view →
UCEC	DFS	Median	All	0.847	0.614	.016	8	view →
PRAD	DFS	Median	All	0.085	0.774	.001	6	view →
KIRP	OS	Median	II,III,IV	0.199	0.771	.030	4	view →
SKCM	OS	Median	III,IV	0.204	0.729	<.001	4	view →
LIHC	DFS	Median	All	0.144	0.559	.001	3	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

MCM3AP–THYM (OS)

Open the THYM breakdown →